The past decade has witnessed unprecedented advances in the diagnosis, treatment, and management of human diseases, driven by precision medicine—an approach that tailors medical interventions to individual patient characteristics (genetics, lifestyle, environment). This review synthesizes 2022–2025 clinical and translational research across three high-burden disease categories: solid tumors (e.g., lung, breast cancer), neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), and infectious diseases (e.g., COVID-19, antimicrobial-resistant infections). Key innovations include AI-enhanced diagnostic imaging, CRISPR-based therapeutic editing, and digital health tools for remote disease management. We address challenges such as access disparities to precision therapies and regulatory hurdles, while highlighting solutions like decentralized clinical trials and equitable biomarker development. This work underscores how translational research is bridging bench discoveries to clinical impact, improving patient outcomes and reducing healthcare burdens globally.

• View pdf

Nanotechnology and biomedical engineering have emerged as transformative forces in clinical medicine, enabling ultra-sensitive diagnosis, targeted therapy, and real-time patient monitoring. This review synthesizes 2022–2025 translational research on their clinical applications across high-burden disease areas: cancer, neurodegenerative disorders, infectious diseases, and cardiovascular conditions. Key innovations include stimuli-responsive nanocarriers for precision drug delivery, wearable biosensors for continuous health tracking, and nanomaterial-based imaging agents for early lesion detection. We address implementation challenges—such as biocompatibility concerns and scalability barriers—while highlighting solutions like surface-functionalized nanomaterials and decentralized manufacturing. This work underscores how these technologies bridge engineering innovation and clinical practice, improving therapeutic efficacy, reducing adverse events, and enhancing patient quality of life globally.

• View pdf

Personalized and digital health solutions—integrating multi-omics data, wearable devices, artificial intelligence (AI), and electronic health records (EHRs)—are reshaping clinical practice by delivering tailored care, improving patient engagement, and optimizing healthcare efficiency. This review synthesizes 2022–2025 translational research on their clinical applications across key domains: chronic disease management, preventive health, pediatric and geriatric care, and global health. Key innovations include AI-driven personalized treatment algorithms for type 2 diabetes, predictive digital biomarkers for early Alzheimer’s disease detection, and remote monitoring platforms for underserved populations. We address implementation challenges—such as data privacy concerns, digital literacy gaps, and interoperability barriers—while highlighting solutions like blockchain-based data security and community-centered digital training. This work underscores how these solutions bridge precision medicine and real-world care, reducing healthcare costs by 20–30% and improving patient-reported outcomes (PROs) in 70% of clinical trials.

• View pdf

Personalized and digital health solutions integrate multi-omics data, AI, wearables, and EHRs to address unmet clinical needs across disease domains. This review synthesizes 2022–2025 translational research, highlighting innovations like AI-driven adaptive therapy for depression (50% PHQ-9 score reduction), wearable-based prenatal monitoring (35% fewer preeclampsia complications), and gender-sensitive AI systems for cancer survivors (87% fatigue alleviation). We address implementation barriers—data privacy (solved via homomorphic encryption), digital literacy (via community training), and interoperability (via FHIR standards)—and present health economic evidence (e.g., $3,200/year cost reduction per T2D patient). These solutions bridge precision medicine and real-world care, improving outcomes in 70% of trials and advancing global health equity.

• View pdf

Chronic pain affects 1.7 billion people globally, with 40% of patients reporting inadequate symptom control due to heterogeneous pain mechanisms and variable treatment responses. Personalized digital health solutions—integrating wearable sensors, AI-driven pain phenotyping, and adaptive digital therapeutics—address these challenges by tailoring interventions to individual pain profiles. This review synthesizes 2022–2025 translational research, highlighting innovations such as multimodal pain monitoring wearables (reducing pain intensity by 32% in clinical trials), AI-based pain subtype classification (89% accuracy in distinguishing nociceptive vs. neuropathic pain), and virtual reality (VR)-enhanced cognitive behavioral therapy (CBT) for centralized pain (45% reduction in pain interference). We address implementation barriers—patient adherence gaps, clinician training needs, and reimbursement challenges—and present health economic evidence (e.g., $2,800 annual cost reduction per patient via reduced opioid use). These solutions advance chronic pain care from a one-size-fits-all approach to precision management, improving patient-reported outcomes (PROs) in 75% of clinical trials.

• View pdf